Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2
159
about 4.2 years
18+
11 sites in FL, MI, MN +6
About this study
This trial is testing a treatment called AU-007 in people with advanced solid tumors. AU-007 will be given alone, or with aldesleukin, or both AU-007 and aldesleukin every two weeks. Once the right dose of AU-007 plus aldesleukin is found, it will also be given with avelumab or nivolumab.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take AU-007
- 2.Take Aldesleukin
- 3.Take Avelumab
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
aldesleukin, avelumab, nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells)
injection, intravenous, infusion
Primary: Establish the maximum tolerated dose (MTD) and/or RP2D, Evaluate the safety and tolerability of AU-007
Secondary: Magnitude of PK changes in the blood after dosing determined by Half-life (T1/2) of AU-007, Magnitude of PK changes in the blood after dosing determined by area under the curve (AUC) of AU-007, Magnitude of PK changes in the blood after dosing determined by maximum concentration (Cmax) of AU-007, Magnitude of PK changes in the blood after dosing determined by time of maximum concentration (Tmax), Magnitude of cytokine changes in the blood after dosing
Oncology